Your browser is no longer supported. Please, upgrade your browser.
Settings
AZN AstraZeneca PLC daily Stock Chart
AZN [NYSE]
AstraZeneca PLC
Index- P/E21.22 EPS (ttm)1.53 Insider Own0.50% Shs Outstand2.53B Perf Week-1.73%
Market Cap82.09B Forward P/E19.21 EPS next Y1.69 Insider Trans0.00% Shs Float2.50B Perf Month11.49%
Income3.87B PEG2.87 EPS next Q0.55 Inst Own15.00% Short Float0.57% Perf Quarter-6.41%
Sales21.74B P/S3.78 EPS this Y23.80% Inst Trans0.83% Short Ratio2.76 Perf Half Y5.60%
Book/sh5.39 P/B6.01 EPS next Y-10.97% ROA6.10% Target Price34.89 Perf Year-4.14%
Cash/sh2.46 P/C13.16 EPS next 5Y7.40% ROE28.40% 52W Range25.55 - 35.60 Perf YTD18.67%
Dividend0.90 P/FCF- EPS past 5Y-17.60% ROI15.00% 52W High-8.93% Beta0.72
Dividend %2.78% Quick Ratio0.70 Sales past 5Y-7.30% Gross Margin82.90% 52W Low26.89% ATR0.47
Employees59700 Current Ratio0.90 Sales Q/Q-9.90% Oper. Margin24.90% RSI (14)60.23 Volatility1.18% 1.17%
OptionableYes Debt/Eq1.44 EPS Q/Q- Profit Margin17.80% Rel Volume0.88 Prev Close32.42
ShortableYes LT Debt/Eq1.23 EarningsOct 26 BMO Payout117.70% Avg Volume5.21M Price32.42
Recom1.80 SMA205.41% SMA504.30% SMA2006.01% Volume0 Change0.00%
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Aug-09-17Upgrade Investec Hold → Buy
Jul-28-17Downgrade Morgan Stanley Overweight → Equal-Weight
May-12-17Upgrade Credit Suisse Underperform → Neutral
Apr-10-17Downgrade Jefferies Buy → Hold
Apr-05-17Downgrade UBS Buy → Neutral
Mar-09-17Initiated Liberum Buy
Dec-09-16Upgrade Leerink Partners Mkt Perform → Outperform
Nov-25-16Upgrade Liberum Hold → Buy
Sep-23-16Initiated Piper Jaffray Overweight
Sep-12-16Upgrade Jefferies Hold → Buy
Aug-29-16Upgrade Argus Hold → Buy
Jul-12-16Initiated Argus Hold
Apr-12-16Downgrade Goldman Neutral → Sell
Mar-15-16Downgrade Jefferies Buy → Hold
Feb-26-16Initiated Cantor Fitzgerald Buy
Feb-08-16Downgrade HSBC Securities Buy → Hold
Jan-19-16Upgrade Barclays Underweight → Equal Weight
Dec-01-15Upgrade Morgan Stanley Underweight → Overweight
Sep-19-17 03:30AM  3 High-Yield Pharmaceutical Stocks Motley Fool
Sep-15-17 10:55AM  Oncology Space in Focus this Week on ESMO Presentations Zacks
Sep-14-17 12:38PM  Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile and Fewer CV Events in Patients with Type-2 Diabetes at Wide Range of CV Risk Business Wire
11:12AM  AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs Zacks
07:54AM  [$$] Moderna Therapeutics raises hopes for drug after human trials Financial Times
07:00AM  Moderna, AstraZeneca heart drug succeeds early-stage trial Reuters
03:30AM  Astra's Farxiga results may open up type 1 diabetes opportunity Reuters
Sep-12-17 05:36PM  Bristol-Myers Reports Positive Results from Melanoma Study Zacks
11:25AM  AstraZeneca's Asthma Candidate Shows Promising Results Zacks
Sep-11-17 03:30PM  Regeneron: When Good Isn't Good Enough Barrons.com
03:17PM  AstraZeneca's Lung Cancer Study Data Promising, Shares Spike Zacks
12:12PM  U.K. stocks edge higher as fears over Irma, North Korea ease MarketWatch
11:21AM  [$$] Teva poaches chief from Danish drugmaker Lundbeck Financial Times
10:42AM  AstraZeneca Wins in Cancer by Going Its Own Way Bloomberg
10:21AM  [$$] AstraZeneca, Merck and Inctye boosted by cancer treatment advances Financial Times
05:47AM  AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results TheStreet.com
05:32AM  Cancer immunotherapy proves itself in earlier-stage disease Reuters
02:10AM  AstraZeneca rebuilds cancer drug hopes with new lung data Reuters
Sep-09-17 11:04AM  AstraZeneca CEO, worried by Brexit, not signing UK government letter Reuters
04:30AM  AstraZeneca rebuilds cancer drug hopes with new lung data Reuters
Sep-08-17 06:46PM  AstraZeneca shares tick higher on lung cancer drug study results MarketWatch
06:24PM  AstraZenecas TAGRISSO® (osimertinib) Shows Potential as a New Standard of Care in 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer at ESMO 2017 Congress Business Wire
06:24PM  AstraZeneca Presents Superior Progression-Free Survival for IMFINZI® (durvalumab) in the Pacific Trial of Patients with Locally-Advanced Unresectable Lung Cancer at ESMO 2017 Congress Business Wire
06:07PM  [$$] AstraZeneca looks for boost from positive trials Financial Times
06:05PM  AstraZeneca rebuilds cancer drug hopes with new lung data Reuters
10:10AM  Company News For Sep 8, 2017 Zacks
08:52AM  AstraZeneca (AZN) Looks Good: Stock Adds 5.1% in Session Zacks
08:10AM  Today's Research Reports on Trending Tickers: AstraZeneca and NewLink Genetics ACCESSWIRE
Sep-07-17 01:28PM  [$$] Hopes for cancer treatment buoy AstraZeneca Financial Times +5.11%
11:06AM  Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise Zacks
10:52AM  Why Regeneron Is Getting Smoked Barrons.com
10:32AM  Merck (MRK) Opts for Buying German Immuno-Oncology Biotech Zacks
10:18AM  AstraZeneca's COPD Candidate Duaklir Reports Positive Data Zacks
08:01AM  FDA puts Celgene's multiple cancer trials on hold Reuters
05:29AM  New AstraZeneca, Amgen drug looks strong rival in severe asthma Reuters
02:48AM  Positive lung drug trial opens path to U.S. market for Circassia Reuters
Sep-06-17 05:07PM  Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma PR Newswire
05:00PM  New AstraZeneca, Amgen biotech drug offers broad asthma relief Reuters
09:06AM  Performance of AstraZenecas Other Products in 2Q17 Market Realist
07:36AM  Performance of AstraZenecas Oncology Segment in 2Q17 Market Realist
Sep-05-17 03:30PM  Lannett receives FDA OK for generic Nexium product American City Business Journals
10:37AM  AstraZeneca Chief Soriot Says He's Worried About Brexit Talks Bloomberg
10:36AM  Performance of AstraZenecas Respiratory Segment in 2Q17 Market Realist
09:07AM  Performance of AstraZenecas CVMD Segment in 2Q17 Market Realist
07:37AM  Performance of AstraZenecas Growth Platforms in 2Q17 Market Realist
Sep-04-17 10:37AM  AstraZenecas Segment-Wise Performance in 2Q17 Market Realist
09:07AM  Chart in Focus: AstraZenecas Revenues in 2Q17 Market Realist
07:38AM  Changes in AstraZenecas Valuation after Its 2Q17 Earnings Market Realist
Sep-01-17 03:43PM  Parkinson's Now a Hot Therapeutic Area: What's Up Lately? Zacks
Aug-31-17 08:48AM  AstraZeneca aims to offset drug setback at big cancer congress Reuters
08:02AM  AstraZeneca's M&A Daydreams Bloomberg
Aug-30-17 01:55PM  [$$] AstraZeneca sinks after Goldman urges caution Financial Times
11:44AM  AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug Zacks
10:30AM  Company News for August 30, 2017 Zacks
Aug-28-17 10:01AM  [$$] AstraZeneca uses AI to tackle neurological disease Financial Times
10:00AM  AstraZeneca taps AI for drug discovery in deal with Berg Reuters
07:00AM  FASLODEX® (fulvestrant) Receives US FDA Approval as Monotherapy for Expanded Use in HR+, HER2- Advanced Breast Cancer Business Wire
06:57AM  Novo Nordisk's Victoza Gets FDA Nod for Label Expansion Zacks
06:56AM  AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting Zacks
06:00AM  3 High-Yield International Stocks Motley Fool
Aug-27-17 06:29PM  [$$] AstraZeneca to announce plans for UK investment Financial Times
Aug-25-17 12:08PM  Better Buy: Inovio Pharmaceuticals, Inc. vs. Novavax, Inc. Motley Fool
07:22AM  Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug Zacks
Aug-22-17 06:05PM  Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval Zacks
07:23AM  3 Most Promising Cancer Drugs in Late-Stage Development Motley Fool
Aug-21-17 07:35PM  [$$] German Biotech Startup Ethris Strikes Respiratory Drug Deal With AstraZeneca The Wall Street Journal
08:50AM  Champions Oncology shares surge 8% on news of AstraZeneca collaboration MarketWatch
Aug-18-17 06:33PM  Tesaro: Losing Its Edge? Barrons.com
04:27PM  Ovarian Cancer Market Still Up For Grabs Barrons.com
10:01AM  AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion Zacks
Aug-17-17 05:23PM  FDA expands use of AstraZeneca/Merck ovarian cancer drug Reuters
04:35PM  FDA approves expanded use of AstraZeneca ovarian cancer drug Reuters
04:22PM  LYNPARZA® (olaparib) Receives Additional FDA Approval in the US for Ovarian Cancer Business Wire
Aug-16-17 01:23PM  AstraZeneca Plc : AZN-US: Dividend Analysis : August 11th, 2017 (record date) : By the numbers : August 16, 2017 Capital Cube
Aug-15-17 04:55AM  Shire Gains as it Seeks European Approval For Dry Eye Treatment TheStreet.com
Aug-14-17 04:10PM  ETFs with exposure to AstraZeneca Plc : August 14, 2017 Capital Cube
03:42PM  Big-name U.S. hedge funds shed healthcare stocks during the rally in Q2 Reuters
Aug-09-17 09:02AM  Biotech: Why Clovis And Tesaro Look Well Positioned Barrons.com
Aug-08-17 02:36PM  A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision Benzinga
12:00AM  Brexit Is Quietly Killing Science Bloomberg
Aug-07-17 04:39PM  Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Intrepid Potash, Inc. (IPI) and Marathon Oil Corporation (MRO) Are 3 of Todays Worst Stocks InvestorPlace
02:15PM  3 High-Yield Stocks for Aggressive Investors Motley Fool
12:01AM  AstraZeneca Takes a Long Shot on Lung Cancer Drug Study Bloomberg
Aug-04-17 05:51PM  Here's Why Agenus Inc. Stock Slipped 13.6% in July Motley Fool
10:00AM  Why AstraZeneca plc Stock Broke Down in July Motley Fool
08:47AM  Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals Zacks
08:05AM  [$$] AstraZeneca is beginning to look a lot like Tesco Financial Times
Aug-03-17 08:09PM  AstraZeneca plc: Buy the Dip? Motley Fool
11:53AM  AstraZeneca's Other Pharmaceutical Products Need to Catch Up GuruFocus.com
09:12AM  The Zacks Analyst Blog Highlights: Merck, Citigroup, AstraZeneca, HSBC and Sprint Zacks
Aug-02-17 06:05PM  Top Research Reports for Merck, Citigroup & AstraZeneca Zacks
03:06PM  Forget BMY's Q2 Earnings, Watch Out For Opdivo Trials Going Forward Forbes
11:41AM  Will Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Catch a Break? InvestorPlace
Aug-01-17 07:00AM  Acalabrutinib Granted Breakthrough Therapy Designation by US FDA for the Treatment of Patients with Mantle Cell Lymphoma Business Wire
04:34AM  AstraZeneca a tricky takeover target after big cancer drug blow Reuters
02:38AM  AstraZeneca gets breakthrough status for blood cancer drug Reuters
Jul-31-17 05:21PM  Foreign Stock Roundup: GSK, Shell, AstraZeneca Beat on Earnings Zacks
04:15PM  How Dow's Merck Is Benefiting On The Backs On AstraZeneca, Bristol Investor's Business Daily
01:45PM  Clovis Sell-Off May Be Overdone TheStreet.com
01:38PM  AstraZeneca Shares Just Fell Sharply, So Here Is Your Next Move TheStreet.com
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. Its marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. It serves primary care and specialty care physicians through distributors and local representative offices. The company's pipeline includes 132 projects, of which 120 are in the clinical phase of development. It has collaboration agreements with Valeant Holdings Ireland, and Eli Lilly and Company; definitive agreement with Foundation Medicine, Inc.; collaborations with FibroGen, Astellas, Pieris Pharmaceuticals Inc, Champions Oncology, Inc., and Takeda Pharmaceutical Company Limited; collaboration and license agreement with Celgene International Sarl; and license agreement with LEO Pharma A/S. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.